摘要
目的探讨同期放化疗加辅助化疗治疗Ⅲ、Ⅳ期鼻咽癌的疗效。方法60例Ⅲ、Ⅳ期鼻咽癌病人随机分入同期放化疗加辅助化疗组(实验组)和单纯放疗组(对照组)。两组均用4MVX线,常规剂量分割。实验组在放疗第1周、第6周同期DDP加5_Fu化疗2疗程,放疗后第4周、第8周辅助化疗2疗程。结果1、3、5年生存率实验组分别为93.3%、80%、56.7%;对照组分别为73.3%、53.3%、30%(P<0.05)。1、3、5年局控率实验组分别为93.3%、73.3%、50%;对照组为70%、46.7%、23.3%(P<0.05)。实验组的急性黏膜反应,脱发等高于对照组,但能耐受,无严重并发症发生。结论同期放、化疗加辅助化疗能提高生存率和局控率,患者均能耐受。
Objective To evaluate the effect of concomitant chemoradiotheray plus adjuvant chemotherapy for stage Ⅲ、Ⅳ nasopharyngeal carcinoma(NPC) Methods 60 patients with stage Ⅲ、Ⅳ NPC were randomized into concomitant chemoradiotherapy plus adjuvant chemotheray group(experiment group) and radiotherapy alone group( control group) The two groups were given by 4MV_X ray and routine dose fraction The patients in experiment group were given by DDP+5_Fu in the first and sixth weeks while radiotherapy,and in the fourth and eighth weeks after radiotherapy Results The overall 1,3,5 year survival rates were respectively 93 3%、80%、56 7% in the experiment group and 73 3%、53 3%、30% in the control group ( P <0 05).1,3,5 year local control rates were respectively 93 3%、73 3%、50% in the experiment group,and 70%、46 7%、23 3% in the control group( P <0 05) The acute mucosa reaction and alopecia in experiment group were higher than that in the control group, but they well tolerated and did not develop any severe complication in the two groups Conclusions The overall survival rate and local control rate of stage Ⅲ、Ⅳ NPC with concomitant chemoradiotherapy plus adjuvant chemotherapy could be improved and the patients could be tolerable
出处
《河南肿瘤学杂志》
2005年第3期195-196,共2页
Henan Journal of Oncology
关键词
同期放
化疗
辅助化疗
Ⅲ
Ⅳ期鼻咽癌
生存率
局控率
concomitant chemoradiotherapy
adjuvant chemotherapy
stage Ⅲ、Ⅳ NPC
overall survival rate
local control rate
